Muliprofile Hospital For Active Treatment Central Onco Hospital OOD — Clinical Trial Site

8 Registered trials

2 Currently recruiting

Organisation

Muliprofile Hospital For Active Treatment Central Onco Hospital OOD

Location

Plovdiv, Bulgaria

Identifier

ORG-100047392

Address

Bulevard Vasil Aprilov 20, 4002, Bulgaria

Departments

0901: Oncology Department
Department of Medical Oncology
Medical Oncology
NA
Radiology Department

Clinical trials at this site (8)

Search interface

A clinical study on SHR3680 combined with androgen deprived therapy (ADT) versus Bicalutamide combined with ADT in treatment of prostate can… Pending

2024-515194-10-00 Metastatic hormone-sensitive prostate cancer with high 5
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting

2022-502352-31-00 Colorectal Cancer (CRC) 5 2025-02-10
Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib Recruiting

2024-512982-15-00 BRCA Mutated Ovarian Cancer Patients, Epithelian ovaria 5 2021-06-28
A study to learn how gadoquatrane moves into, through, and out of the body and how safe it is in children aged 0 to less than 18 years, who … Ended

2022-501883-17-00 Contrast enhancement in magnetic resonance imaging in c 5 2023-10-16
A study to compare how well gadoquatrane works and its safety with an already available contrast agent for MRI in people with known or suspe… Ended

2022-501884-41-00 Contrast enhancement in magnetic resonance imaging for 5 2023-09-29
A study to compare the effects and safety of gadoquatrane with an already used available contrast agent for MRI tests in people with any kno… Ended

2022-501885-24-00 Contrast enhancement in magnetic resonance imaging for 5 2023-09-20
Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended

2023-505458-16-00 Gastric and Gastroesophageal Junction Cancer With FGFR2 5 2022-09-13
A Study Evaluating Bemarituzumab in Solid Tumors with FGFR2b Overexpression Ended

2023-505455-44-00 Solid tumours 9 2022-06-29